- Home
- INCY vs AR Comparison
INCY vs AR Comparison
Compare INCY & AR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- AR
- Stock Information
- Founded
- INCY 1991
- AR 2002
- Country
- INCY United States
- AR United States
- Employees
- INCY N/A
- AR N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- AR Oil & Gas Production
- Sector
- INCY Health Care
- AR Energy
- Exchange
- INCY Nasdaq
- AR Nasdaq
- Market Cap
- INCY 13.4B
- AR 12.7B
- IPO Year
- INCY 1993
- AR 2013
- Fundamental
- Price
- INCY $58.21
- AR $34.42
- Analyst Decision
- INCY Hold
- AR Buy
- Analyst Count
- INCY 20
- AR 18
- Target Price
- INCY $74.00
- AR $40.94
- AVG Volume (30 Days)
- INCY 2.3M
- AR 6.1M
- Earning Date
- INCY 04-29-2025
- AR 04-30-2025
- Dividend Yield
- INCY N/A
- AR N/A
- EPS Growth
- INCY N/A
- AR N/A
- EPS
- INCY 0.15
- AR 0.18
- Revenue
- INCY $4,241,216,999.00
- AR $4,297,764,000.00
- Revenue This Year
- INCY $12.21
- AR $36.14
- Revenue Next Year
- INCY $9.20
- AR $3.16
- P/E Ratio
- INCY $345.39
- AR $187.85
- Revenue Growth
- INCY 14.76
- AR N/A
- 52 Week Low
- INCY $50.35
- AR $24.53
- 52 Week High
- INCY $83.95
- AR $42.63
- Technical
- Relative Strength Index (RSI)
- INCY 40.69
- AR 44.02
- Support Level
- INCY $57.05
- AR $32.70
- Resistance Level
- INCY $59.95
- AR $34.51
- Average True Range (ATR)
- INCY 2.76
- AR 2.55
- MACD
- INCY 0.18
- AR -0.36
- Stochastic Oscillator
- INCY 46.45
- AR 36.35
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About AR Antero Resources Corporation
Antero Resources, based in Denver, engages in the exploration for and production of natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.